Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors
Status:
Active, not recruiting
Trial end date:
2022-03-11
Target enrollment:
Participant gender:
Summary
GSK1795091 is being developed for administration in combination with other immune system
modulators for the treatment of cancers. The study will be conducted in two parts. In Part 1,
dose escalation will be performed to identify combination dose levels comprising GSK1795091
with either 24 milligrams (mg) GSK3174998 (Part 1a), 80 mg GSK3359609 (Part 1b), or 200 mg
pembrolizumab (Part 1c). One dose level of GSK3174998, GSK3359609, or pembrolizumab with up
to 5 dose levels of GSK1795091 are planned for evaluation. In Part 2 (dose-expansion),
subjects will receive a single dose level of GSK1795091 as identified based on data from Part
1, in combination with either GSK3174998, GSK3359609, or pembrolizumab.